Phytochemicals in the treatment of inflammation-associated diseases: the journey from preclinical trials to clinical practice

Frontiers in Pharmacology

Pharmacology

Akib Nisar¹  Manasi Deshpande²  Om Prakash³  Suresh Jagtap⁴  Abhay Harsulkar⁵  Prabhakar Ranjekar⁶  Suresh Vyavahare⁷ 

[1] Biochemical Sciences Division, Rajiv Gandhi Institute of IT and Biotechnology, Bharati Vidyapeeth Deemed to be University, Pune, Maharashtra, India;Department of Dravyagun Vigyan, College of Ayurved, Bharati Vidyapeeth Deemed to be University, Pune, Maharashtra, India;Department of Microbiology, Immunology and Parasitology, University Health Sciences Center, New Orleans, LA, United States;Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, United States;Herbal Medicine, Interactive Research School for Health Affairs, Bharati Vidyapeeth Deemed to be University, Pune, Maharashtra, India;Herbal Medicine, Interactive Research School for Health Affairs, Bharati Vidyapeeth Deemed to be University, Pune, Maharashtra, India;Pharmaceutical Biotechnology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed to be University, Pune, Maharashtra, India;Innovation Biologicals Pvt., Ltd., Pune, Maharashtra, India;Shatayu Ayurved and Research Centre, Solapur, Maharashtra, India;

关键词: inflammation;    phytochemical;    medicinal drug;    preclinical;    clinical;   

DOI  :  10.3389/fphar.2023.1177050

 received in 2023-03-01, accepted in 2023-04-27,  发布年份 2023

来源: Frontiers

【 摘 要 】

Advances in biomedical research have demonstrated that inflammation and its related diseases are the greatest threat to public health. Inflammatory action is the pathological response of the body towards the external stimuli such as infections, environmental factors, and autoimmune conditions to reduce tissue damage and improve patient comfort. However, when detrimental signal-transduction pathways are activated and inflammatory mediators are released over an extended period of time, the inflammatory process continues and a mild but persistent pro-inflammatory state may develop. Numerous degenerative disorders and chronic health issues including arthritis, diabetes, obesity, cancer, and cardiovascular diseases, among others, are associated with the emergence of a low-grade inflammatory state. Though, anti-inflammatory steroidal, as well as non-steroidal drugs, are extensively used against different inflammatory conditions, they show undesirable side effects upon long-term exposure, at times, leading to life-threatening consequences. Thus, drugs targeting chronic inflammation need to be developed to achieve better therapeutic management without or with a fewer side effects. Plants have been well known for their medicinal use for thousands of years due to their pharmacologically active phytochemicals belonging to diverse chemical classes with a number of these demonstrating potent anti-inflammatory activity. Some typical examples include colchicine (alkaloid), escin (triterpenoid saponin), capsaicin (methoxy phenol), bicyclol (lignan), borneol (monoterpene), and quercetin (flavonoid). These phytochemicals often act via regulating molecular mechanisms that synergize the anti-inflammatory pathways such as increased production of anti-inflammatory cytokines or interfere with the inflammatory pathways such as to reduce the production of pro-inflammatory cytokines and other modulators to improve the underlying pathological condition. This review describes the anti-inflammatory properties of a number of biologically active compounds derived from medicinal plants, and their mechanisms of pharmacological intervention to alleviate inflammation-associated diseases. The emphasis is given to information on anti-inflammatory phytochemicals that have been evaluated at the preclinical and clinical levels. Recent trends and gaps in the development of phytochemical-based anti-inflammatory drugs have also been included.

【 授权许可】

Unknown   
Copyright © 2023 Nisar, Jagtap, Vyavahare, Deshpande, Harsulkar, Ranjekar and Prakash.